Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S. Kittai, Philip A. Thompson, P Manoj et al.|Journal of Clinical Oncology|2024Cited by 43
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b StudyNirav N. Shah, Talha Munir, Zulfa Omer et al.|Blood|2024Cited by 27
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S. Kittai, Jennifer A. Woyach, Ying Huang et al.|Blood Cancer Journal|2025Cited by 12
Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trialZulfa Omer, Wojciech Jurczak, Alexey V. Danilov et al.|Blood|2025Cited by 3